Figure and Table | Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Table 1. Baseline Characteristics of the Study Population (n = 44).

From: Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Characteristics		Value^a, n (%)
Age, years, median [range]		68 [31–83]
Sex (male)		31 (70.5%)
ECOG PS at time of pembrolizumab monotherapy^b
	0	31 (70.5%)
	1	10 (22.7%)
	2	3 (6.8%)
Smoking status
	Current smoker or ever smoked	35 (79.5%)
	Never smoked	9 (20.4%)
Pathological subtype
	Squamous cell carcinoma	17 (38.6%)
	Non-squamous NSCLC	27 (61.4%)
PD-L1 expression
	≥ 50% (high)	27 (61.4%)
	1–49% (low)	17 (38.6%)
EGFR status in non-squamous NSCLC
	Mutant	3 (6.8%)
Number of prior chemotherapy regimens
	0	22 (50%)
	1	13 (29.5%)
	≥ 2	9 (20.5%)
Development of irAEs		31 (70.5%)
Development of severe irAEs		10 (22.7%)
Onset of irAEs, weeks, median [range]		3.3 [0–28]

» Back to article page

Table 2. Categorization of irAEs in Patient Cohort.

From: Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

	n (%)	Grade of irAEs, n 1/2/3/4/5
Skin reaction	18 (40.9%)	14/1/3/0/0
Pneumonitis	10 (22.7%)	0/5/4/0/1
Infusion reaction	8 (18.2%)	5/3/0/0/0
Hepatitis	4 (9.1%)	2/0/1/1/0
Thyroid dysfunction	4 (9.1%)	4/0/0/0/0
Microhematuria	2 (4.5%)	2/0/0/0/0
Myocarditis	1 (2.3%)	0/0/0/1/0
Pancreatitis	1 (2.3%)	0/0/1/0/0
Enteritis	1 (2.3%)	0/1/0/0/0
Eye symptom	1 (2.3%)	1/0/0/0/0
Myositis/peripheral neuropathy	0 (0%)	0/0/0/0/0

» Back to article page

Table 3. Characteristics of Patients with irAEs (irAE Group) and without irAEs (Non-irAE Group) (n = 44)^a.

From: Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Variables		Univariate analysis			Multivariate analysis
Variables		irAE group^b (n = 31)	non-irAE group^c (n = 13)	P	Odds rate	95% CI	P^h
Sex (male), n (%)		22 (71.0%)	9 (69.2%)	1.0^f	-	-	-
Age, years, median [range]		68 [37–83]	71 [31–80]	0.77^g	-	-	-
Pathological subtype
	Squamous cell carcinoma, n (%)	13 (41.9%)	4 (30.8%)	0.74^f	-	-	-
	Non-squamous NSCLC, n (%)	18 (58.0%)	9 (69.2%)
Smoking (ex, current), n (%)		26 (83.9%)	9 (69.2%)	0.41^f	-	-	-
ECOG PS 0, n (%)		25 (80.6%)	6 (46.1%)	0.033^f	4.4	0.85–22.8	0.076
Primary treatment, n (%)		20 (64.5%)	2 (15.3%)	0.007^f	-	-	-
High PD-L1 expression, n (%)		24 (77.4%)	3 (23.1%)	0.002^f	11	2.1–54.4	0.004
Best response, n CR/PR/SD/PD		0/16/14/1	0/2/5/6		-	-	-
	Response rate, n (%)^d	16 (51.6%)	2 (15.4%)	0.043^f	-	-	-
	Disease control rate, n (%)^e	30 (96.8%)	7 (53.8%)	0.001^f	-	-	-

» Back to article page

Table 4. Comparison of the Development of irAEs and Severe irAEs^a in Patients with High PD-L1 Expression Based on Primary Therapy and Secondary Therapy or More (n = 27)^b.

From: Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

	Primary therapy (n = 22)	Second therapy or more (n = 5)	P^c
irAEs, n (%)	20 (90.9%)	4 (80.0%)	0.47
Severe irAEs, n (%)	6 (27.3%)	2 (40.0%)	0.62

» Back to article page

Table 5. Comparison of the Development of irAEs and Severe irAEs^a in Previously-treated Patients Based on High and Low PD-L1 Expression (n = 22)^b.

From: Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

	High PD-L1 expression (n = 5)	Low PD-L1 expression (n = 17)	P^c
irAEs, n (%)	4 (80.0%)	7 (41.2%)	0.31
Severe irAEs, n (%)	2 (40.0%)	2 (11.7%)	0.21

» Back to article page